Purchase Order N0025921P0334
Award Date 8/27/21
Potential Completion Date 10/1/24
Potential Value $218K
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed NAICS Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not listed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Health Agency awarded a $104,256 firm fixed-price purchase order to Cerus Corporation on September 30, 2019, for INTERCEPT Platelet Small Volume Sets, with performance through September 3, 2024. The contract was awarded without a set-aside designation to Cerus Corporation, a Concord, California-based biomedical products manufacturer specializing in blood safety technologies. Cerus's INTERCEPT Blood System uses riboflavin and ultraviolet light technology to inactivate pathogens in...
- This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The contract is for the delivery of INTERCEPT Platelet Processing Sets, which are used to inactivate pathogens in blood platelets. The contract has a ceiling value of $295,760.00 and an ultimate completion date of January 31, 2022. Cerus Corporation has consistently secured sole-source...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Cerus Corporation, a for-profit manufacturer of the INTERCEPT Blood System, a pathogen reduction technology for platelets and plasma. The $369,384 contract is for the supply of INTERCEPT Platelet Processing Sets, Dual Storage Containers, and maintenance services for INTERCEPT Blood System illuminators to support medical readiness and blood product safety at military healthcare facilities. The contract has...
- The Defense Health Agency (DHA) awarded a firm fixed-price purchase order to Cerus Corporation on October 1, 2024, for INTERCEPT Platelet Processing Sets to support the Naval Base San Diego Laboratory. The contract carries a ceiling value of $232,128.00 and extends through September 30, 2027. No set-aside designation was used in this award. Cerus Corporation, headquartered in Concord, California, is a biomedical products manufacturer specializing in blood safety technologies and pathogen...
- This firm-fixed-price purchase order was awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company, for the provision of INTERCEPT Platelet Processing Sets. Valued at $137,664.00, the contract does not have a set-aside designation. Cerus has received over 20 previous prime federal contract awards from agencies including the DoD, VA, and HHS to provide pathogen reduction technologies, equipment, and associated services to support military and veterans' medical...
- The Defense Health Agency awarded a $258.2K firm fixed-price purchase order to Cerus Corporation for Intercept Platelet Pathogen Reduction Sets at Tripler Army Medical Center in Hawaii. The contract, awarded October 1, 2021, with an ultimate completion date of September 30, 2025, represents a sole-source procurement under FAR 13.106-1(b)(1)(i), as Cerus Corporation is the only provider capable of meeting the government's specialized requirements. The Intercept system utilizes riboflavin and...
- The Defense Health Agency issued a purchase order to Cerus Corporation for CERUS INTERCEPT Platelet Processing Sets on October 1, 2025, with a ceiling value of $367,100. Performance is located in Concord, California, and the order extends through September 30, 2030. The procurement, structured as firm fixed-price, originated from a sources sought notice posted by Tripler Army Medical Center in June 2025 to assess market capabilities for specialized blood processing equipment. The INTERCEPT Blood...
- The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...
- The Defense Health Agency awarded a $82.8K firm fixed-price purchase order to Cerus Corporation on February 7, 2020, for maintenance services on two illuminators used in the INTERCEPT Blood System. The contract, which includes a base year plus four option years, is scheduled for completion by February 8, 2025, with performance occurring at a location in Japan. This award was not set-aside for small businesses or other designated categories. Cerus Corporation, a biomedical products manufacturer...
- <p>The Defense Health Agency awarded a purchase order to Cerus Corporation for $214,560 on February 21, 2025, for INT2540B drop shipment for platelet processing under the INTERCEPT Platelet product line. Performance will be executed in Portsmouth, Virginia, with ultimate completion targeted for February 23, 2028. The order is firm fixed price with no small business set-aside applied.</p>